Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

In This Article:

For the quarter ended September 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $175.69 million, up 14.2% over the same period last year. EPS came in at $1.06, compared to -$0.29 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $155.06 million, representing a surprise of +13.30%. The company delivered an EPS surprise of +171.79%, with the consensus EPS estimate being $0.39.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Net product sales- Trokendi XR: $15.30 million compared to the $10.50 million average estimate based on three analysts. The reported number represents a change of -25.7% year over year.

  • Revenues- Net product sales- Oxtellar XR: $29.80 million compared to the $19.57 million average estimate based on three analysts. The reported number represents a change of +0.7% year over year.

  • Revenues- Net product sales- Qelbree: $62.40 million versus the three-analyst average estimate of $60.01 million. The reported number represents a year-over-year change of +68.2%.

  • Revenues- Net product sales: $170.30 million versus $149.66 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.3% change.

  • Revenues- Royalty revenues: $5.39 million versus $5.93 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.9% change.

  • Revenues- Net product sales- GOCOVRI: $35.60 million compared to the $34.36 million average estimate based on three analysts. The reported number represents a change of +8.2% year over year.

  • Revenues- Net product sales- Other: $7.30 million versus $7.77 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

  • Revenues- Net product sales- APOKYN: $19.90 million versus the two-analyst average estimate of $16.25 million. The reported number represents a year-over-year change of -7.4%.

View all Key Company Metrics for Supernus here>>>

Shares of Supernus have returned +6.1% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Waiting for permission
Allow microphone access to enable voice search

Try again.